Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1

Cardiovascular Research

Volumn 93, Issue 4, 2012, Pages 682-693

  Bauer, Philip M ^a   Bauer, Eileen M ^a   Rogers, Natasha M ^a   Yao, Mingyi ^a   Feijoo Cuaresma, Monica ^b   Pilewski, Joseph M ^a   Champion, Hunter C ^a   Zuckerbraun, Brian S ^a   Calzada, Maria J ^b   Isenberg, Jeffrey S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Caveolin 1; CD47; eNOS; Pulmonary arterial hypertension; Reactive oxygen species

Indexed keywords

CAVEOLIN 1; CD47 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; SUPEROXIDE; THROMBOSPONDIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; UPREGULATION;

ANIMALS; ANOXIA; ANTIGENS, CD47; CASE-CONTROL STUDIES; CAVEOLIN 1; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; UP-REGULATION;

EID: 84857982754     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr356     Document Type: Review

References (48)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S. (Pubitemid 38759713)
3. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004;68:75-103. (Pubitemid 39093882)
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43: 5S-12S. (Pubitemid 38759712)
5. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895. (Pubitemid 38252536)
6. Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 2005;111: 2126-2133. (Pubitemid 40577909)
7. Konduri GG, Ou J, Shi Y, Pritchard KA Jr. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 2003;285:H204-H211. (Pubitemid 36736431)
8. Lakshminrusimha S, Wiseman D, Black SM, Russell JA, Gugino SF, Oishi P et al. The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2007;293:H1491-H1497. (Pubitemid 47367193)
9. Kobs RW, Chesler NC. The mechanobiology of pulmonary vascular remodeling in the congenital absence of eNOS. Biomech Model Mechanobiol 2006;5:217-225. (Pubitemid 44618437)
10. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299: 818-824. (Pubitemid 33104947)
11. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y et al. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 1996;271:6518-6522. (Pubitemid 26095467)
12. Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R et al. Endothelialspecific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci USA 2005;102:204-209. (Pubitemid 40094453)
13. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 1997;272: 18522-18525. (Pubitemid 27318186)
14. Sowa G, Pypaert M, Sessa WC. Distinction between signaling mechanisms in lipid rafts vs. caveolae.Proc Natl Acad Sci USA 2001;98:14072-14077. (Pubitemid 33116026)
15. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449-2452. (Pubitemid 32917325)
16. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002;277:8635-8647. (Pubitemid 34968330)
17. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002;99:11375-11380. (Pubitemid 34920933)
18. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ et al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 2007;204:2373-2382. (Pubitemid 47529323)
19. Wunderlich C, Schmeisser A, Heerwagen C, Ebner B, Schober K, Braun-Dullaeus RC et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther 2008;21:507-515. (Pubitemid 351625932)
20. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009;119:2009-2018.
21. Achcar RO, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
22. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J 2007;21:2970-2979. (Pubitemid 47372763)
23. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109:1945-1952. (Pubitemid 46348191)
24. Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005; 24:110-123. (Pubitemid 40693635)
25. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141-13146. (Pubitemid 41324992)
26. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-26080. (Pubitemid 44401813)
27. Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-481.
28. Zuckerbraun BS, Chin BY, Wegiel B, Billiar TR, Czsimadia E, Rao J et al. Carbon monoxide reverses established pulmonary hypertension. J Exp Med 2006;203:2109-2119. (Pubitemid 44352232)
29. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
30. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Haromy A et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630-2641. (Pubitemid 43948012)
31. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010;30: 716-723.
32. Antezana AM, Antezana G, Aparicio O, Noriega I, Velarde FL, Richalet JP. Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. Eur Respir J 1998;12:1181-1185. (Pubitemid 28545633)
33. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998;101:982-992. (Pubitemid 28125276)
34. Burt C, Pepke-Zaba J, Falter F. Pulmonary arterial hypertension. Curr Vasc Pharmacol 2010;8:412-420.
35. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601.
36. Sessa WC. eNOS at a glance. J Cell Sci 2004;117:2427-2429. (Pubitemid 38877838)
37. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002;7: 149-164. (Pubitemid 35346221)
38. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF et al. Differential interactions of thrombospondin-1,-2, and-4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284:1116-1125.
39. Lim EJ, Smart EJ, Toborek M, Hennig B. The role of caveolin-1 in PCB77-induced eNOS phosphorylation in human-derived endothelial cells. Am J Physiol Heart Circ Physiol 2007;293:H3340-3347. (Pubitemid 350230874)
40. Zheng C, Wang L, Li R, Ma B, Tu L, Xu X et al. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol 2010;43:740-749.
41. Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH et al. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 2008;294:L1250-L1259.
42. Redout EM, Wagner MJ, Zuidwijk MJ, Boer C, Musters RJ, van Hardeveld C et al. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res 2007;75:770-781. (Pubitemid 47243719)
43. Maxhimer JB, Shih HB, Isenberg JS, Miller TW, Roberts DD. Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg 2009;124:1880-1889.
44. Lobysheva I, Rath G, Sekkali B, Bouzin C, Feron O, Gallez B et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011;31:2098-2105.
45. Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004;143:159-165. (Pubitemid 39280035)
46. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999;43: 532-541. (Pubitemid 29369252)
47. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000;477:258-262. (Pubitemid 30450177)
48. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009;21:52-62.